Allergy Therapeutics said Tuesday its house-dust mite immunotherapy demonstrated highly significant symptom improvement in a clinical trial. In the observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year, the company said. The company's latest research at EAACI included an overview of the early-phase pre-clinical developments for the group's planned recombinant peanut vaccine and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy. 'The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products,’ said Manuel Llobet,' Chief Executive Officer. At 9:26am: (LON:AGY) Allergy Therapeutics PLC share price was 0p at 25.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.